ALG-125755
Chronic Hepatitis B (CHB)
Phase 1Status Unclear (Deprioritized)
Key Facts
Indication
Chronic Hepatitis B (CHB)
Phase
Phase 1
Status
Status Unclear (Deprioritized)
Company
About Aligos Therapeutics
Aligos Therapeutics is a clinical-stage biotech focused on developing best-in-class therapies for chronic liver and viral diseases, specifically chronic hepatitis B (CHB) and MASH. The company employs a targeted, chemistry-driven approach to design small molecules with optimized pharmacological profiles. Its strategy centers on a lean, experienced team with a proven track record in hepatology and virology drug development, aiming to advance a focused pipeline through key clinical milestones. Despite a challenging financial position with a low market valuation, its progress is defined by upcoming Phase 2 data for its lead assets.
View full company profileTherapeutic Areas
Other Chronic Hepatitis B (CHB) Drugs
| Drug | Company | Phase |
|---|---|---|
| CARG-201 | CaroGen | Pre-clinical |
| Anti-HBVxCD3 | Ancora Bio | Preclinical |
| VIR-2218 + VIR-3434 | Vir Biotechnology | Phase 2 |
| Pevifoscorvir sodium (ALG-000184) | Aligos Therapeutics | Phase 2 |